Inhibition of the JAK-STAT pathway, for example, has emerged as a viable treatment regimen for several conditions including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease [50]. This evidence concerns the gene SOAT1 and psoriatic arthritis.